#United States #Austin, Texas #digital health #Significo #JSTAR Capital

Significo Achieves Significant Milestone with Series B Funding

Significo, a prominent player in the realm of health AI and digital therapeutics, is making headlines with the successful closure of its Series B financing round. This funding, spearheaded by JSTAR Capital Investments and their Horizon Fund II, has propelled Significo's valuation to an impressive $100 million. This strategic move positions the company to enhance its mission in the digital health sector and to pursue an aggressive strategy of acquiring synergistic digital health companies.

The recent financing is tailored to empower Significo in expanding its portfolio and amplifying its market presence within an increasingly fragmented healthcare industry. The company is now eyeing several acquisition opportunities that seamlessly align with its existing platforms, notably Balm—its innovative digital therapeutic and condition management solution—and Recco, which provides personalized health recommendations.

Rick McCartney, the CEO of Significo, emphasized the significance of this funding by stating, "Digital health is at an inflection point. Patients, providers, and payors are looking for scalable, clinically validated solutions that deliver real outcomes." He further noted that the backing from JSTAR Capital Investments will not only enable Significo to scale its platforms but also to consolidate top-notch digital health innovations under a unified banner. The overarching aim is to streamline technology adoption for healthcare providers, ultimately driving substantial health outcomes at a population level.

Significo's growth trajectory has been bolstered by solid commercial traction, including collaborations with leading insurers, health systems, and distribution networks. By merging proven digital therapeutics into one comprehensive platform, Significo intends to diminish fragmentation while boosting patient engagement. This integration is crucial for establishing a sustainable model for the reimbursement and adoption of digital therapeutics.

Jared Leger, Managing Director at JSTAR Capital Investments, expressed enthusiasm about leading this funding round, underscoring the firm’s commitment to supporting Significo in transforming the digital health landscape. Additionally, Evan Pritchard, another Managing Director at the firm, recognized the company's impressive track record of execution and emphasized the need for their vision in the industry.

With this funding, Significo is set to cultivate growth initiatives across various dimensions including product development, global expansion, and strategic acquisitions. This multifaceted approach is designed to further its mission to make digital therapeutics readily available, effective, and integrated into everyday healthcare delivery.

About Significo

Significo stands out as a global leader in health AI and digital therapeutics, working to provide solutions that empower patients, healthcare providers, and payors with clinically validated interventions and personalized care. Their flagship products include Balm—an advanced digital therapeutic delivery solution—and Recco, which helps in delivering personalized health advice. Significo collaborates with health systems, insurers, and employers worldwide to facilitate scalable and effective digital health solutions.

For more information, visit www.significo.com.

About JSTAR Capital Investments

JSTAR Capital Investments is dedicated to nurturing growth-focused organizations within the healthcare, technology, and life sciences sectors. The firm, through its Horizon Fund II, extends both capital and strategic guidance to innovative entrepreneurs aiming to shape the future of their industries. For further details, refer to jstarinvestments.com.